APELLIS PHARMACEUTICALS INC. - COMMON STOCK

Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results

31 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Oct 2022 15:05:00 By Nasdaq GlobeNewswire

Apellis Announces 24-Month Phase 3 Post Hoc Results Showing Treatment with Pegcetacoplan Led to Preservation of Function in High-Risk Areas of the Retina in Patients with Geographic Atrophy (GA) at AAO Annual Meeting

30 Sep 2022 16:30:00 By Nasdaq GlobeNewswire

Apellis Announces Four Oral Presentations of Data from the Phase 3 DERBY and OAKS Studies of Pegcetacoplan in Geographic Atrophy (GA) to be Presented at the American Academy of Ophthalmology Annual Meeting

30 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference

12 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Sep 2022 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 Sep 2022 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces 24-Month Results Showing Increased Effects Over Time with Pegcetacoplan in Phase 3 DERBY and OAKS Studies in Geographic Atrophy (GA)

24 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Reports Second Quarter 2022 Financial Results

08 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Host Conference Call on Aug 8, 2022 to Discuss Second Quarter 2022 Financial Results

01 Aug 2022 15:05:01 By Nasdaq GlobeNewswire

Apellis Announces Agreements to Exchange Approximately $75.6 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock

27 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of Geographic Atrophy (GA)

19 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Apellis Announces Five Oral Presentations in Geographic Atrophy (GA) Highlighted at the ASRS Annual Scientific Meeting

14 Jul 2022 09:01:15 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Apellis Expands R&D Collaboration with Affilogic to Develop Targeted Complement Therapies for Delivery into the Brain

22 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI® (pegcetacoplan) for PNH at EHA 2022 Congress

10 Jun 2022 02:00:00 By Nasdaq GlobeNewswire

Apellis and Sobi Announce First Patient Dosed in Phase 3 VALIANT Study of Pegcetacoplan for IC-MPGN and C3G, Rare Kidney Diseases with High Unmet Medical Need

07 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 Jun 2022 15:05:00 By Nasdaq GlobeNewswire

Apellis Pharmaceuticals to Present at Upcoming Investor Conferences

01 Jun 2022 15:05:00 By Nasdaq GlobeNewswire